A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
HALEON PLC ORD GBP0.01 operates in the Drug Manufacturers - Specialty & Generic industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 14.6B | 14.6B | 14.4B | 14.1B | 13.4B | 13.1B |
| Net Income | 2.2B | 2.2B | 1.8B | 1.3B | 1.4B | 2.0B |
| EPS | $0.24 | $0.24 | $0.20 | $0.14 | $0.14 | $0.21 |
| Free Cash Flow | 3.1B | 3.1B | 2.6B | 2.3B | 2.2B | 1.6B |
| ROIC | 12.4% | 7.7% | 6.4% | 5.2% | 4.7% | 4.9% |
| Gross Margin | 64.2% | 64.2% | 60.7% | 59.7% | 60.6% | 62.3% |
| Debt/Equity | 0.00 | 0.52 | 0.63 | 0.76 | 0.85 | 0.14 |
| Dividends/Share | $0.09 | $0.09 | $0.08 | $0.05 | $0.34 | $0.17 |
| Operating Income | 3.2B | 3.2B | 2.8B | 2.5B | 2.2B | 2.3B |
| Operating Margin | 21.9% | 21.9% | 19.6% | 17.7% | 16.8% | 17.2% |
| ROE | 10.1% | 10.4% | 8.9% | 6.4% | 4.9% | 5.6% |
| Shares Outstanding | 8,962M | 8,962M | 9,127M | 9,202M | 9,730M | 9,530M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 12.7B | 13.1B | 13.4B | 14.1B | 14.4B | 14.6B | 14.6B |
| Gross Margin | 59.7% | 62.3% | 60.6% | 59.7% | 60.7% | 64.2% | 64.2% |
| R&D | -392M | -353M | -370M | -388M | -381M | -417M | -417M |
| SG&A | -5.4B | -5.6B | -5.5B | -5.5B | -5.7B | -5.8B | -5.8B |
| EBIT | 2.1B | 2.3B | 2.2B | 2.5B | 2.8B | 3.2B | 3.2B |
| Op. Margin | 16.2% | 17.2% | 16.8% | 17.7% | 19.6% | 21.9% | 21.9% |
| Net Income | 1.5B | 2.0B | 1.4B | 1.3B | 1.8B | 2.2B | 2.2B |
| Net Margin | 11.9% | 15.1% | 10.3% | 9.3% | 12.8% | 15.1% | 15.1% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 5.0% | 4.9% | 4.7% | 5.2% | 6.4% | 7.7% | 12.4% |
| ROE | 4.5% | 5.6% | 4.9% | 6.4% | 8.9% | 10.4% | 10.1% |
| ROA | N/A | 4.2% | 3.1% | 3.1% | 4.3% | 5.1% | 5.1% |
| Cash Flow | |||||||
| Op. Cash Flow | 1.8B | 1.9B | 2.5B | 2.6B | 2.9B | 3.5B | 3.5B |
| Free Cash Flow | 1.5B | 1.6B | 2.2B | 2.3B | 2.6B | 3.1B | 3.1B |
| Owner Earnings | 1.8B | 1.9B | 2.5B | 2.5B | 2.8B | 3.4B | 3.4B |
| CapEx | 286M | 313M | 375M | 292M | 320M | 425M | 425M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 425M |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 15.8% | 16.8% | 14.7% | 11.1% | 10.9% | 12.2% | 12.2% |
| Capital Allocation | |||||||
| Dividends Paid | 3.1B | 1.6B | 3.3B | 484M | 729M | 808M | 808M |
| Dividend Yield | N/A | N/A | 10.2% | 1.3% | 1.8% | 1.8% | 2.5% |
| Share Buybacks | 0 | 0 | 0 | 0 | 148M | 199M | 199M |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.4% | 0.6% |
| Stock-Based Comp | N/A | 0 | 18M | 95M | 130M | 114M | 114M |
| Debt Repayment | 13M | 0 | 1.9B | 690M | 719M | 1.8B | 1.8B |
| Balance Sheet | |||||||
| Net Debt | N/A | 4.6B | 16.4B | 14.5B | 10.1B | 9.6B | -1.7B |
| Cash & Equiv. | 429M | 569M | 843M | 1.3B | 2.9B | 1.7B | 1.7B |
| Long-Term Debt | N/A | N/A | N/A | N/A | 11.1B | 10.3B | 10.3B |
| Debt/Equity | N/A | 0.14 | 0.85 | 0.76 | 0.63 | 0.52 | 0.00 |
| Interest Coverage | 59.2 | 86.2 | 7.1 | 5.0 | 5.7 | 7.1 | 7.1 |
| Equity | 33.8B | 36.4B | 20.3B | 20.9B | 20.7B | 21.7B | 21.7B |
| Total Assets | N/A | 47.4B | 42.9B | 42.5B | 43.9B | 43.1B | 43.1B |
| Total Liabilities | N/A | 11.0B | 22.6B | 21.6B | 23.1B | 21.3B | 21.3B |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | 51.6B | 32.9B | 34.3B | 34.9B | 36.8B | 36.8B |
| Working Capital | N/A | 1.4B | -383M | 222M | -120M | -506M | -506M |
| Current Assets | N/A | 7.2B | 5.0B | 6.0B | 7.3B | 6.0B | 6.0B |
| Current Liabilities | N/A | 5.8B | 5.4B | 5.8B | 7.4B | 6.5B | 6.5B |
| Per Share Data | |||||||
| EPS | 0.16 | 0.21 | 0.14 | 0.14 | 0.20 | 0.24 | 0.24 |
| Owner EPS | 0.19 | 0.20 | 0.26 | 0.27 | 0.31 | 0.38 | 0.38 |
| Book Value | 3.55 | 3.82 | 2.08 | 2.27 | 2.27 | 2.42 | 2.42 |
| Cash Flow/Share | 0.19 | 0.20 | 0.26 | 0.28 | 0.32 | 0.39 | 0.25 |
| Dividends/Share | 0.32 | 0.17 | 0.34 | 0.05 | 0.08 | 0.09 | 0.09 |
| Shares Out. | 9.5B | 9.5B | 9.7B | 9.2B | 9.1B | 9.0B | 9.0B |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | 27.7 | 29.0 | 23.8 | 20.6 | 14.8 |
| P/FCF | N/A | N/A | 17.6 | 16.2 | 16.6 | 14.8 | 10.6 |
| EV/EBIT | N/A | N/A | 24.3 | 21.0 | 19.0 | 17.2 | 9.6 |
| Price/Book | N/A | N/A | 1.9 | 1.8 | 2.1 | 2.1 | 1.5 |
| Price/Sales | N/A | N/A | 2.9 | 2.7 | 3.0 | 3.1 | 2.2 |
| FCF Yield | N/A | N/A | 5.7% | 6.2% | 6.0% | 6.8% | 9.4% |
| Market Cap | 0 | 0 | 38.2B | 37.7B | 43.6B | 45.1B | 32.3B |
| Avg. Price | 0.00 | 0.00 | 3.34 | 4.08 | 4.48 | 4.93 | 3.61 |
| Year-End Price | 0.00 | 0.00 | 3.92 | 4.10 | 4.78 | 5.03 | 3.61 |
HALEON PLC ORD GBP0.01 passes 5 of 9 quality checks, suggesting mixed fundamentals.
HALEON PLC ORD GBP0.01 trades at 14.8x trailing earnings, compared to its 15-year median P/E of 25.7x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 10.6x vs a median of 16.4x. The company's 5-year average ROIC is 5.8% with a gross margin of 61.5%. Total shareholder yield (dividends + buybacks) is 3.1%. At current prices, the estimated annualized return to fair value is +9.3%.
HALEON PLC ORD GBP0.01 (HLN-L) has a current P/E ratio of 14.8, compared to its historical median P/E of 25.7. The stock is currently considered Cheap based on its historical valuation range.
HALEON PLC ORD GBP0.01 (HLN-L) has a 5-year average return on invested capital (ROIC) of 5.8%. This is below average and may indicate limited pricing power.
HALEON PLC ORD GBP0.01 (HLN-L) has a market capitalization of $32.3B. It is classified as a large-cap stock.
Yes, HALEON PLC ORD GBP0.01 (HLN-L) pays a dividend with a trailing twelve-month yield of 2.50%. The company also returns capital through share buybacks, with a buyback yield of 0.62%.
Based on historical P/E analysis, HALEON PLC ORD GBP0.01 (HLN-L) appears cheap. The current P/E of 14.8 is 43% below its historical median of 25.7. The estimated fair value CAGR (P/E method) is 6.0%.
HALEON PLC ORD GBP0.01 (HLN-L) operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
HALEON PLC ORD GBP0.01 (HLN-L) reported annual revenue of $14.6 billion in its most recent fiscal year, based on SEC EDGAR filings.
HALEON PLC ORD GBP0.01 (HLN-L) has a net profit margin of 15.1%. This is a healthy margin.
HALEON PLC ORD GBP0.01 (HLN-L) generated $3.1 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
HALEON PLC ORD GBP0.01 (HLN-L) has a debt-to-equity ratio of 0.52. This indicates moderate leverage.
HALEON PLC ORD GBP0.01 (HLN-L) reported earnings per share (EPS) of $0.24 in its most recent fiscal year.
HALEON PLC ORD GBP0.01 (HLN-L) has a return on equity (ROE) of 10.4%. This indicates moderate shareholder returns.
HALEON PLC ORD GBP0.01 (HLN-L) has a 5-year average gross margin of 61.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for HALEON PLC ORD GBP0.01 (HLN-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
HALEON PLC ORD GBP0.01 (HLN-L) has a book value per share of $2.42, based on its most recent annual SEC filing.
No recent press releases.